Parameter | Value | References |
---|---|---|
Baseline Fracture Risks | based on Fx type, age, and gender, BMD | |
Fracture Relative Risks - GIOP | by fracture type based on age | [13] |
Fracture after Fracture and Second Fracture Relative Risks | based on fracture type and age | |
Drug Costs | Teriparatide- Avg. Daily Cost: €14.74 | [15] |
Alendronate – Avg. Daily Cost: €0.42 | ||
Acute and Long-Term Direct Fracture Costs | by age and fracture type | |
Currency SEK to € Conversion | 9.0335 ; 12 month average ending December 2011 | [16] |
Continuing 6 Month Care Costs | €201 (months 1–6,13-18) | [17] |
€194 (months 7–12) | ||
Natural Mortality | Swedish Life Tables based on age and gender; adjusted to remove osteoporosis fracture deaths | |
Fracture Mortality | based on age and gender; | [13] |
0.007 (65 year male) to 0.0375 (90+ year old female) | ||
Relative Risk of Mortality Post Fracture | For hip fractures and vertebral fractures; ranges: 2.5 (year 1) to 1.0 (year 7) | |
Base Health Utilities | by age; from 0.84 (through age 50) to 0.65 (age 85) | [21] |
Fracture Utility Multipliers | first year and subsequent years, by fracture type | [13] |
Teriparatide Anti-Fracture Efficacies Relative Risks | by fracture type and treatment period | |
Bisphosphonate Anti-Fracture Efficacies Relative Risks | by fracture type and treatment period | [13] |
Teriparatide Discontinuation | 3, 9, and 15 month values interpolated to 6 month cycles | [22] |
Bisphosphonate Discontinuation | by 6 month cycle | [23] |